Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07876154 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to learn if Iparomlimab/Tuvonralimab combined with nab-paclitaxel and cisplatin as neoadjuvant treatment can treat locally advanced cervical cancer in adult female patients. It will also learn about the safety of this combination regimen. The main questions it aims to answer are: What is the pathological complete response (pCR) rate after neoadjuvant combination therapy? What are the objective response rate, progression-free survival, overall survival, biomarker changes and tumor immune microenvironment changes in participants receiving this regimen? There is no comparison group in this single-arm study. Participants will: * Receive neoadjuvant treatment with Iparomlimab/Tuvonralimab, albumin-bound paclitaxel and cisplatin * Undergo radical surgery after completion of neoadjuvant therapy * Receive scheduled imaging, blood and tissue biomarker tests * Be followed up regularly for survival and safety assessment.
Trial Details
NCT Number NCT07876154
Lead Sponsor Xijing Hospital
Conditions
(from sponsor)		 Locally Advanced Cervical Cancer
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov